Dohj LLC Takes Position in Biogen Inc. (NASDAQ:BIIB)

Dohj LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,675 shares of the biotechnology company’s stock, valued at approximately $951,000.

Several other institutional investors have also modified their holdings of BIIB. OFI Invest Asset Management bought a new stake in shares of Biogen during the 3rd quarter worth approximately $26,000. Gladius Capital Management LP bought a new stake in shares of Biogen during the 3rd quarter worth approximately $28,000. KB Financial Partners LLC lifted its stake in shares of Biogen by 105.1% during the 3rd quarter. KB Financial Partners LLC now owns 121 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 62 shares during the last quarter. CVA Family Office LLC bought a new stake in shares of Biogen during the 4th quarter worth approximately $36,000. Finally, Baker Avenue Asset Management LP lifted its stake in shares of Biogen by 215.5% during the 3rd quarter. Baker Avenue Asset Management LP now owns 183 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 125 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on BIIB. Piper Sandler decreased their price target on Biogen from $350.00 to $325.00 and set an “overweight” rating for the company in a research note on Wednesday, February 14th. Oppenheimer decreased their price target on Biogen from $290.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, April 1st. Royal Bank of Canada reissued an “outperform” rating and set a $364.00 price target on shares of Biogen in a research note on Tuesday, March 5th. Finally, Wedbush raised their price objective on Biogen from $213.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday. Ten research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $293.88.

Biogen Stock Up 3.2 %

Shares of Biogen stock traded up $6.44 during trading on Friday, reaching $208.90. The company’s stock had a trading volume of 1,894,098 shares, compared to its average volume of 1,185,437. The company has a quick ratio of 1.26, a current ratio of 2.10 and a debt-to-equity ratio of 0.41. The company has a market cap of $30.42 billion, a price-to-earnings ratio of 26.08, a P/E/G ratio of 2.13 and a beta of -0.02. Biogen Inc. has a 1-year low of $189.44 and a 1-year high of $319.76. The company has a 50-day simple moving average of $212.55 and a two-hundred day simple moving average of $233.57.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.45 by $0.22. The firm had revenue of $2.29 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Biogen had a return on equity of 14.83% and a net margin of 12.07%. The business’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.40 EPS. As a group, equities analysts forecast that Biogen Inc. will post 15.57 earnings per share for the current year.

Insider Transactions at Biogen

In other news, Director Eric K. Rowinsky purchased 455 shares of the stock in a transaction on Thursday, February 15th. The stock was bought at an average price of $222.54 per share, with a total value of $101,255.70. Following the transaction, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Biogen news, insider Priya Singhal sold 419 shares of Biogen stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $239.45, for a total transaction of $100,329.55. Following the completion of the sale, the insider now owns 4,516 shares of the company’s stock, valued at approximately $1,081,356.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Eric K. Rowinsky purchased 455 shares of the stock in a transaction on Thursday, February 15th. The shares were purchased at an average cost of $222.54 per share, with a total value of $101,255.70. Following the transaction, the director now owns 20,629 shares in the company, valued at approximately $4,590,777.66. The disclosure for this purchase can be found here. Insiders sold 882 shares of company stock valued at $202,030 in the last quarter. 0.60% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.